Rinvoq helped 55% of severe alopecia patients regrow hair

Signals Inbox·September 2, 2026·Biopharma

Rinvoq, a drug already used for inflammatory diseases such as rheumatoid arthritis, is showing dramatic hair regrowth in severe alopecia areata. The headline sounds like a strange drug repurposing story, but the deeper point is that immune-targeting JAK inhibitors are turning a once poorly treated autoimmune condition into a competitive drug market.

Q1What do the official trial results show?

AbbVie's Phase 3 data show 55.0% and 54.3% of patients on the 30 mg dose reached at least 80% scalp-hair coverage by week 24 in two replicate studies.

Q2Did anyone regrow all their hair?

Yes. Around 20% to 23% of patients on 30 mg reached complete scalp coverage at week 24, rising to roughly 36% to 37% by week 52 in the two studies.

Q3Why call it an arthritis drug?

Upadacitinib was first developed and approved for immune diseases including rheumatoid arthritis. Alopecia areata is also autoimmune, so the same JAK1 pathway can be targeted to stop immune attacks on hair follicles.

Q4Is this still experimental?

Not in Europe. The European Commission approved Rinvoq for severe alopecia areata in July 2026 for adults and adolescents aged 12 and older. AbbVie has also submitted the indication to the FDA.

Q5Why does this matter?

Severe alopecia used to have few reliably effective options. Multiple JAK inhibitors now show large response rates, turning immune-driven hair loss into a pharmaceutical category where meaningful regrowth can be measured rather than merely hoped for.